The Evolving Role of Immunotherapy in Stage III Non-Small Cell Lung Cancer

被引：3

作者：

Perdrizet, Kirstin ^{[1
,2
]}

Cheema, Parneet K. ^{[1
,2
]}

机构：

[1] Univ Toronto, Div Med Oncol, Toronto, ON M5S IA8, Canada

[2] William Osler Hlth Syst, Med Oncol Hematol, Brampton, ON L6R 3J7, Canada

来源：

CURRENT ONCOLOGY | 2021年 / 28卷 / 06期

关键词：

immunotherapy; NSCLC; Stage III; adjuvant; neoadjuvant; concurrent chemotherapy and radiation; checkpoint inhibitors; MAJOR PATHOLOGICAL RESPONSE; IMMUNE-CHECKPOINT BLOCKADE; NEOADJUVANT DURVALUMAB; CONCURRENT CHEMORADIOTHERAPY; ADJUVANT-CISPLATIN; PLUS CHEMOTHERAPY; NSCLC; SURVIVAL; RADIOTHERAPY; TRIAL;

D O I：

10.3390/curroncol28060451

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The management of Stage III non-small cell lung cancer (NSCLC) is complex and requires multidisciplinary input. Since the publication of the PACIFIC trial (consolidative durvalumab post concurrent chemotherapy and radiation in Stage III disease) which showed improved survival for patients in the immunotherapy arm, there has been much interest in the use of immunotherapy in the Stage III setting. In this review, we explore the biologic and clinical rationale for the use of immunotherapy in Stage III NSCLC, present previously published and upcoming data in the neoadjuvant, adjuvant, and concurrent realms of Stage III management, and discuss unanswered questions and challenges moving forward.

引用

页码：5408 / 5421

页数：14

共 55 条

[1] Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial [J].

Albain, Kathy S. ;

Swann, R. Suzanne ;

Rusch, Valerie W. ;

Turrisi, Andrew T., III ;

Shepherd, Frances A. ;

Smith, Colum ;

Chen, Yuhchyau ;

Livingston, Robert B. ;

Feins, Richard H. ;

Gandara, David R. ;

Fry, Willard A. ;

Darling, Gail ;

Johnson, David H. ;

Green, Mark R. ;

Miller, Robert C. ;

Ley, Joanne ;

Sause, Willliam T. ;

Cox, James D. .

LANCET, 2009, 374 (9687) :379-386

[2] Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial [J].

Altorki, Nasser K. ;

McGraw, Timothy E. ;

Borczuk, Alain C. ;

Saxena, Ashish ;

Port, Jeffrey L. ;

Stiles, Brendon M. ;

Lee, Benjamin E. ;

Sanfilippo, Nicholas J. ;

Scheff, Ronald J. ;

Pua, Bradley B. ;

Gruden, James F. ;

Christos, Paul J. ;

Spinelli, Cathy ;

Gakuria, Joyce ;

Uppal, Manik ;

Binder, Bhavneet ;

Elemento, Olivier ;

Ballman, Karla, V ;

Formenti, Silvia C. .

LANCET ONCOLOGY, 2021, 22 (06) :824-835

[3]

[Anonymous], 2018, CAN CANC STAT 2018

[4] Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer [J].

Antonia, S. J. ;

Villegas, A. ;

Daniel, D. ;

Vicente, D. ;

Murakami, S. ;

Hui, R. ;

Yokoi, T. ;

Chiappori, A. ;

Lee, K. H. ;

de Wit, M. ;

Cho, B. C. ;

Bourhaba, M. ;

Quantin, X. ;

Tokito, T. ;

Mekhail, T. ;

Planchard, D. ;

Kim, Y. -C. ;

Karapetis, C. S. ;

Hiret, S. ;

Ostoros, G. ;

Kubota, K. ;

Gray, J. E. ;

Paz-Ares, L. ;

de Castro Carpeno, J. ;

Wadsworth, C. ;

Melillo, G. ;

Jiang, H. ;

Huang, Y. ;

Dennis, P. A. ;

Ozguroglu, M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (20) :1919-1929

[5] Combining surgery and immunotherapy: turning an immunosuppressive effect into a therapeutic opportunity [J].

Bakos, Orneala ;

Lawson, Christine ;

Rouleau, Samuel ;

Tai, Lee-Hwa .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6

[6] Immune Checkpoint Inhibition With Chemoradiotherapy in Stage III Non-small-cell Lung Cancer: A Systematic Review and Meta-analysis of Safety Results [J].

Balasubramanian, Adithya ;

Onggo, James ;

Gunjur, Ashray ;

John, Thomas ;

Parakh, Sagun .

CLINICAL LUNG CANCER, 2021, 22 (02) :74-82

[7] Neoadjuvant atezolizumab (A) for resectable non-small cell lung cancer (NSCLC): Results from the phase II PRINCEPS trial [J].

Besse, B. ;

Adam, J. ;

Cozic, N. ;

Chaput-Gras, N. ;

Planchard, D. ;

Mezquita, L. ;

Remon Masip, J. ;

Lavaud, P. ;

Naltet, C. ;

Gazzah, A. ;

de Montpreville, V. Thomas ;

Ghigna, M. -R. ;

Mussot, S. ;

Fadel, E. ;

Mabille, L. ;

Duchemann, B. ;

Barlesi, F. ;

Soria, J-C. ;

Caramella, C. ;

Mercier, O. .

ANNALS OF ONCOLOGY, 2020, 31 :S794-S795

[8] Progression after the next line of therapy (PFS2) and updated OS among patients (pts) with advanced NSCLC and PD-L1 tumor proportion score (TPS) ≥50% enrolled in KEYNOTE-024. [J].

Brahmer, Julie R. ;

Rodriguez-Abreu, Delvys ;

Robinson, Andrew George ;

Hui, Rina ;

Csoszi, Tibor ;

Fulop, Andrea ;

Gottfried, Maya ;

Peled, Nir ;

Tafreshi, Ali ;

Cuffe, Sinead ;

O'Brien, Mary ;

Rao, Suman ;

Hotta, Katsuyuki ;

Leiby, Melanie A. ;

McLean, Jessica ;

Shentu, Yue ;

Rangwala, Reshma A. ;

Reck, Martin .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35

[9] Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data [J].

Burdett, Sarah ;

Rydzewska, Larysa H. M. ;

Tierney, Jayne F. ;

Auperin, Anne ;

Le Pechoux, Cecile ;

Le Chevalier, Thierry ;

Pignon, Jean-Pierre .

LANCET, 2014, 383 (9928) :1561-1571

[10] Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancer [J].

Cascone, Tina ;

Weissferdt, Annikka ;

Godoy, Myrna C. B. ;

William, William N., Jr. ;

Leung, Cheuk H. ;

Lin, Heather Y. ;

Basu, Sreashi ;

Yadav, Shalini S. ;

Pataer, Apar ;

Mitchell, Kyle G. ;

Khan, Md Abdul Wadud ;

Shi, Yushu ;

Haymaker, Cara ;

Solis, Luisa M. ;

Parra, Edwin R. ;

Kadara, Huam ;

Wistuba, Ignacio I. ;

Sharma, Padmanee ;

Allison, James P. ;

Ajami, Nadim J. ;

Wargo, Jennifer A. ;

Jenq, Robert R. ;

Gibbons, Don L. ;

Lee, J. Jack ;

Swisher, Stephen G. ;

Vaporciyan, Araa ;

Heymach, John, V ;

Sepesi, Boris .

NATURE COMMUNICATIONS, 2021, 12 (01)

← 1 2 3 4 5 6 →